



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Sara S. Bacus et al.

Docket No.: 6155-US-NP  
(former 02-434-A)

Serial No: 10/600,129

Group Art Unit: 1643

Filed: June 19, 2003

Examiner: Anne L. Holleran

For: Method for Predicting Response to Epidermal Growth Factor Receptor-Directed Therapy

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**STATEMENT UNDER 37 C.F.R. 3.73(b)**

Abgenix, Inc. (hereinafter "Abgenix"), a corporation of the State of Delaware, and Immunex Corporation (hereinafter "Immunex"), a corporation of the State of Washington, are the assignees of the entire right, title, and interest in the above-identified U.S. patent application. Documentary evidence of a chain of title from the original owner(s) to Abgenix and Immunex are demonstrated by:

☐ the enclosed copy of an Assignment, the original of which is being filed for recordation by the United States Patent and Trademark Office.

OR

☒ the assignments recorded in the United States Patent and Trademark Office at:  
Reel 015071 Frame 0836 and Reel 015094 Frame 0990.

The undersigned, whose titles are supplied below, is empowered to sign this statement on behalf of Abgenix and Immunex.

**REVOCATION OF PREVIOUS POWER OF ATTORNEY AND NEW POWER OF  
ATTORNEY BY ASSIGNEE**

Amgen hereby revokes all previous powers of attorney given in the above-identified application and hereby appoints the registered practitioners at Customer Number **21069** to prosecute this application, to make and to transact all business in the Patent and Trademark Office connected therewith.

**REQUEST FOR CHANGE OF CORRESPONDENCE ADDRESS**

Please send all future correspondence and direct telephone calls to Customer Number **21069**.

Date: April 13, 2009

ABGENIX, INC.

IMMUNEX CORPORATION

By Stuart L. Watt  
Stuart L. Watt

By Stuart L. Watt  
Stuart L. Watt

Title: Vice President, Law

Title: Vice President, Law & Intellectual Property